American Society of Clinical Oncology (ASCO), 2023


  1. Real-world Early Outcomes of Axicabtagene Ciloleucel for Relapsed or Refractory (R/R) Follicular Lymphoma (FL).
  2. Circulating tumor DNA (ctDNA) by clonoSEQ to monitor residual disease after axicabtagene ciloleucel (axi-cel) in large B-cell lymphoma (LBCL).
  3. ZUMA-23: A global, Phase 3, randomized controlled study of axicabtagene ciloleucel versus standard of care as first-line therapy in patients with high-risk large B-cell lymphoma.
  4. ZUMA-22: A Phase 3, randomized controlled study of axicabtagene ciloleucel (axi-cel) versus standard-of-care therapy in patients with relapsed or refractory (R/R) follicular lymphoma (FL).
  5. Impact of age, prior therapies, and subsequent transplant on long-term outcomes of adults with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3.
  6. Real-world Outcomes of Brexucabtagene Autoleucel (Brexu-cel) for Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL): A CIBMTR Subgroup Analysis by Prior Treatment
  7. Primary overall survival analysis of the phase 3 randomized ZUMA 7 study of axicabtagene ciloleucel versus standard of care therapy in relapsed/refractory large B-cell lymphoma.